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Pseudoxanthoma Elasticum-Like Phenotype with
Cutis Laxa and Multiple Coagulation Factor
Deficiency Represents a Separate Genetic Entity
Olivier M. Vanakker1,2,3, Ludovic Martin4, Dealba Gheduzzi5, Bart P. Leroy1,6, Bart L. Loeys1,
Veronica I. Guerci7, Dirk Matthys3, Sharon F. Terry8, Paul J. Coucke1, Ivonne Pasquali-Ronchetti5
and Anne De Paepe1
Data on six patients with a Pseudoxanthoma Elasticum (PXE)-like phenotype, characterized by excessive skin
folding (resembling cutis laxa) and a deficiency of the vitamin K-dependent clotting factors (II, VII, IX, and X) are
presented. A comparison is made between the clinical, ultrastructural, and molecular findings in these patients
and those seen in classic PXE and cutis laxa, respectively. Clinical overlap with PXE is obvious from the skin
manifestations of yellowish papules or leathery plaques with dot-like depressions at presentation, angioid
streaks and/or ocular peau d’orange, and fragmentation and calcification of elastic fibers in the dermis.
Important phenotypic differences with PXE include much more severe skin laxity with spreading toward the
trunk and limbs with thick, leathery skin folds rather than confinement to flexural areas, and no decrease in
visual acuity. Moreover, detailed electron microscopic analyses revealed that alterations of elastic fibers as well
as their mineralization were slightly different from those in classic PXE. Molecular analysis revealed neither
causal mutations in the ABCC6 gene (ATP-binding cassette subfamily C member 6), which is responsible for PXE,
nor in VKORC1 (vitamin K 2,3 epoxide reductase), known to be involved in vitamin K-dependent factor
deficiency. However, the GGCX gene (gamma-glutamyl carboxylase), encoding an enzyme important for
g-carboxylation of gla-proteins, harbored mutations in six out of seven patients analyzed. These findings all
support the hypothesis that the disorder indeed represents a separate clinical and genetic entity, the molecular
background of which remains to be unraveled.
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INTRODUCTION
Pseudoxanthoma Elasticum (PXE – OMIM no. 264800) is an
autosomal-recessive multisystem disease, affecting mainly
the eyes (peau d’orange (Pd’O), angioid streaks (AS), loss of
central vision owing to neovascularization and subsequent
exudation, and hemorrhage), the skin (yellowish papules or
plaques of coalesced papules on the neck and in flexural
areas), and the cardiovascular system (diffuse occlusive
arterial disease). In some patients, the skin lesions can be
progressive, evolving toward excessive skin folding in the
flexural areas (McKusick, 1966; Neldner, 1988; Hu et al.,
2003; Chassaing et al., 2005). Histologically, it is character-
ized by fragmentation and mineralization of the elastic fibers
in the reticular dermis.
PXE is caused by mutations in the ABCC6 gene (ATP-
binding cassette subfamily C member 6 – chromosome
16p13.1) encoding an ATP-dependent transmembrane trans-
porter whose substrate and pathophysiological role remain to
be elucidated (Bergen et al., 2000; Le Saux et al., 2000;
Ringpfeil et al., 2000; Struk et al., 2000).
Cutis laxa (OMIM nos. 123700; 219100) is a hetero-
geneous group of acquired or inherited (autosomal-recessive
or -dominant) disorders, characterized by loose, sagging, and
redundant skin. The clinical findings can be limited to the
skin, although extracutaneous manifestations (pulmonary
emphysema, hernias, intestinal diverticuli, ocular anterior
segment abnormalities) have also been described (Lewis
et al., 2004; Ringpfeil, 2005).
The histopathology of cutis laxa, using van Giesson stains,
can reveal both loss and fragmentation of elastic fibers in the
reticular dermis (Lewis et al., 2004; Ringpfeil, 2005).
Although the molecular background of cutis laxa is largely
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unknown, causal mutations have been reported in the elastin
gene (ELN on chromosome 7q11.2) and in the fibulin-5 gene
(FBLN5 on chromosome 14q32.1) (Tassabehji et al., 1998;
Loeys et al., 2002; Markova et al., 2003).
We describe six patients in whom a clinical diagnosis of
PXE was initially made and subsequently supported by light
microscopy on skin biopsy. However, these patients progres-
sively developed excessive skin folds which, although
initially confined to the flexural areas, spread both toward
the abdomen and limbs. Moreover, all six patients were also
found to have a deficiency of the vitamin K-dependent
coagulation factors (factors II, VII, IX, X). Two patients had a
history of or suggestive of cerebral aneurysms.
This phenotype has been previously described in a few
case reports (MacMillan and Vickers, 1971; Rongioletti et al.,
1989; Le Corvaisier-Pieto et al., 1996) but to our knowledge,
no molecular data are available.
We have undertaken a detailed electron microscopy study
of the ultrastructural characteristics of the dermis of these
patients. Additionally, a molecular study of the ABCC6 gene
was performed as well as an initial candidate gene screening
for the clotting disorder.
Based on the clinical, structural, and molecular findings
on these six novel patients, we hypothesize that their
condition represents a separate genetic entity.
RESULTS
Clinical description
Six Caucasian patients with initial signs of typical yellowish
papules that coalesce and form plaques with regularly
depressed dots, sometimes referred to as cutaneous
‘‘Pd’O’’ (Figure 1b), developed an increasing number
of excessive, leathery skin folds, which gradually spread
beyond the flexural areas of the body (Figure 1c–f).
The papular and leathery skin lesions with dot-like
depressions, however, remained stable. Fundoscopy
revealed only limited AS and/or Pd’O without comets
temporal to the macula in patients 1 through 4 and normal
visual acuity in all patients (Figure 1a). During follow-up,
both fundus appearance and visual acuity remained un-
changed.
Cardiovascular investigations, including clinical examina-
tion, electrocardiography, and ultrasonography, showed
subclinical atherosclerotic plaques in the lower limbs in
two patients and vascular occlusion with intermittent claudi-
cation in one patient. In patient 1, two cerebral aneurysms
were subsequently discovered at age 36 and 46 years and
successfully treated.
Routine blood coagulation tests revealed a
prolonged prothrombin time with decreased levels of the
vitamin K-dependent clotting factors (Table 1). Clinical
manifestations were present in only two patients. Patient 3
suffered three meningeal hemorrhages over a period of 20
years. Further bleeding events include a postpartum hemo-
rrhage after delivery of her only child and one episode of
unexplained hematemesis. Patient 5 had a history of
epistaxis, spontaneous gingival bleeding, and severe vaginal
hemorrhages.
Details on the individual phenotypes can be found in
Table 2.
a
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Figure 1. Clinical characteristics of the presented phenotype in several patients. Note (a) a mild retinopathy, (b) skin lesions featuring yellowish papules that
coalesce and form plaques with regularly depressed dots, and (c–f) generalized excessive and leathery skin folds.
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Ultrastructural findings
By light microscopy, the overall appearance of the dermis
was identical to that typical of PXE. The reticular dermis
presented areas in which elastic fibers were polymorphous,
fragmented, and mineralized, as shown by Von Kossa
staining.
At the ultrastructural level, the alterations of the
elastic fibers could be better analyzed and compared
with those of PXE and revealed peculiar features. Although
the two classical types of mineral precipitates, fine granular
and bulky calcifications, were present, elastic fibers
had a more fragmented and mottled appearance compared
to those typical of PXE. In longitudinal sections, elastic
fibers appeared to be made of loose, thin strands of
polymorphous elastin material. Moreover, very often miner-
alization occupied only a limited area within huge
elastic fibers and was organized as peculiar small
electron-dense crystal-like precipitates. Several collagen
fibrils were fused forming the so-called ‘‘collagen flowers’’
(Figure 2).
Table 1. Biochemical analysis results of the PT and vitamin K-dependent coagulation factor activity levels
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Normal
PT (INR) 1.81 1.84 1.97 2.19 1.7 1.9 0.8–1.2
Factor II (% nl)1 66 61 38 38 20 18 100 (90–150)
Factor VII (% nl) 26 39 50 62 74 88 100 (90–150)
Factor IX (% nl) 70 71 103 90 48 56 100 (90–150)
Factor X (% nl) 15 40 20 17 20 18 100 (90–150)
PT, prothrombin time; INR, International Normalized Ratio.
1Percentage of normal activity.
Table 2. Comparison of the phenotypical, histopathological, and molecular characteristics of the six presented
patients (1–6) and the four previously reported cases (7–10)
1 2 3 4 5 6 7 8 9 10
Sex F F F F F M M M F F
Age1 46 47 67 32 46 44 40 33 24 24
Age of onset skin symptoms1 18 13 3 18 NA NA 16 Puberty Puberty Puberty
Positive familial history     NA NA   + +
Generalized skin folds/laxity + + + + + + + + + +
Yellowish papules  + + + + + NA NA  
Dot-like depressions + + + + + + NA NA  
Yellow mucosal pattern  + +  NA NA NA NA NA NA
Esthetic surgery performed  + + + NA NA NA NA NA NA
Positive calcium stain + + + + + + + + + +
AS + + + +      
Ocular Pd’O  +  +   NA   
Decreased visual acuity          
Clotting deficiency + + + + + + + + + +
Abnormal bleeding tendency   +  +  +  + +
Subclinical atherosclerosis  + +  +    + +
Weak peripheral pulsations    +   NA NA NA NA
Cerebral aneurysms +  ?  NA NA    
ABCC6 mutations     NA NA  NA NA NA
VKORC1 mutations        NA NA NA
AS, angioid streaks; F, female; M, male; NA, not available; Pd’O, peau d’orange.
1In years.
Case 7: Le Corvaisier-Pieto et al., 1996; case 8: Rongioletti et al., 1989; cases 9 and 10: MacMillan and Vickers, 1971.
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Molecular results
Molecular analysis of the ABCC6 gene, responsible for PXE,
failed to identify mutations in all six patients, and in one
patient reported earlier (Le Corvaisier-Pieto et al., 1996).
Sequencing of the VKORC1 gene (vitamin K 2,3 epoxide
reductase), responsible for vitamin K recycling, did not reveal
any mutation. Analysis of the second gene involved in the
clotting disorder, GGCX (gamma-glutamyl carboxylase),
revealed six novel missense mutations and one novel
nonsense mutation in the seven patients, including the
patient reported earlier (Table 3). Mutations occurred in
homozygous or compound heterozygous form in four
patients. In two other patients, only one mutation could
be detected. These mutations affected amino acids which
were fully or almost fully conserved in Mus musculus,
Rattus norvegicus, Fugu rubripes, Anopheles, and Drosophi-
la. None of these mutations were found in 200 control
chromosomes of unrelated healthy Europeans.
DISCUSSION
The six patients described show clinical overlap with PXE,
hence the initial diagnosis of a severe form of that disorder.
All initially manifested skin manifestations considered typical
of PXE, such as yellowish papules and/or plaques with
dot-like depressions characterized by light microscopy as
fragmentation and calcification of elastic fibers in the
reticular dermis. Moreover, the observed retinopathy (AS
originating from the optic disc, Pd’O lesions temporal to the
macula) in these patients was anatomically similar if not
identical to that seen in PXE.
However, clinical, ultrastructural, and molecular differ-
ences allow us to discriminate the phenotype of these
patients from PXE and from cutis laxa (Table 4).
First, these patients are remarkable for the severity of their
skin involvement. Increased skin laxity and excessive skin
folding can be seen in PXE, but usually these features remain
confined to the flexural areas of the body (McKusick, 1966;
Neldner, 1988; Hu et al., 2003; Chassaing et al., 2005). In
contrast, in these patients, the leathery skin folds extended
toward the limbs and abdomen leaving only the face, hands,
and feet unaffected. Interestingly, the speed of evolution of
the skin laxity was quite different between patients. Whereas
progression over several years in patients 1 and 4 led to the
very severe skin phenotype in their early thirties, patient 3
already suffered from severe skin laxity during her childhood,
and patient 2 manifested rapid progression during puberty.
Secondly, the fundus examination revealed only limited
AS and/or mild Pd’O. Moreover, visual acuity remained
stable in all four patients during follow-up. In contrast, in
PXE, up to 60% of patients suffer from considerable loss of
central vision. Although sample size is small, this suggests
that in this PXE-like phenotype, the retinopathy is milder and
has a more benign prognosis.
Third, electron microscopy revealed that dermis altera-
tions, especially those of elastic fibers, were similar, but not
identical, to those in PXE. Similarities with PXE were that
(i) changes occurred in the same areas of the dermis; (ii) not
a
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Figure 2. Ultrastructural characteristics of the presented phenotype. At low
magnification electron microscopy, dermal alterations are mainly located
in the reticular dermis and appear very similar to those in PXE. The great
majority of elastic fibers are polymorphous, fragmented, and mineralized and
are surrounded by rather thick and compact collagen bundles (a and b).
Both the fine granular (a and b, asterisks) and the bulky types (a and b, arrows)
of elastic fiber mineralization, always described in PXE, are present.
However, different from classical PXE, the great majority of the apparently
normal elastic fibers are organized as rather thin and polymorphous strands
of elastin material connected into a loose network (c and d, arrows).
Moreover, calcification affects often the marginal areas of elastic fibers
(d–f, arrowheads), whereas in PXE mineralized fine deposits are always
in the core of elastic fibers. Similar to PXE, collagen fibrils can be fused
forming the so called ‘‘collagen flowers’’ (f, inset, arrows). Bar¼1 mm.
Table 3. Mutations found in the six presented cases
(1–6) and one earlier reported case (7)
Patient Allele 1 Exon Allele 2 Exon
1 p.W493S c.1506G4C 12 p.W493S c.1506G4C 12
2 — — — — — —
3 p.R476C c.1454C4T 10 — — —
4 p.R476H c.1455G4A 10 — — —
5 p.Q374X c.1149C4T 8 p.G537Y c.1339G4T 12
6 p.Q374X c.1149C4T 8 p.G537Y c.1339G4T 12
7 p.F299S c.924T4C 8 p.G558R c.1700G4A 12
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all elastic fibers were mineralized, but in those that were, the
two types of mineralization already described in PXE were
present; (iii) fibroblasts had huge cisternae of the endoplas-
mic reticulum; (iv) lateral fusion of collagen fibrils were
observed in one patient. However, elastic fibers, either
mineralized or not, were different from that typical of PXE.
In patients 1, 2, and 3, they were often made of aggregates of
distinct strands of elastin and mineralization was mostly
confined to the periphery of the fibers (case 1) or was
associated to the most compact areas of the fibers (cases 2
and 3). In contrast, in patient 4 elastic fibers were huge and
compact and mineralization was very severe. Moreover,
electron-dense crystal-like bodies, never observed in PXE,
were present in all patients in the central core of finely
mineralized elastic fibers.
Finally, molecular analysis of the ABCC6 gene, respon-
sible for PXE, failed to identify mutations in all of the patients,
including the one reported earlier.
Classical cutis laxa syndromes could also be excluded
because neither the retinopathy nor mineralization of elastic
fibers is seen in those disorders (Krill and Archer, 1972; Lewis
et al., 2004).
A second feature of the phenotype is a deficiency of the
clotting factors II, VII, IX, and X, which are synthesized in the
liver and depend on vitamin K for their function. Such
deficiency can either be acquired or congenital (Oldenburg
et al., 2000; Sadler, 2004; Zhang and Ginsburg, 2004).
However, in our patients there was no evidence for an
acquired form, as they did not exhibit any hepatic disease or
malabsorption.
Congenital deficiency of the vitamin K-dependent factors
(VKCFD) is a very rare autosomal-recessive disorder. It is
caused either by mutations in the GGCX gene (VKCFD1 –
OMIM no. 277450) on chromosome 2p12, or in the VKORC1
gene (VKCFD2 – OMIM no. 607473) on chromosome
16p11.2. These genes encode a vitamin K-dependent
carboxylase and vitamin K 2,3 epoxide reductase, respec-
tively (Oldenburg et al., 2000; Li et al., 2004; Rost et al.,
2004a, b; Zhang and Ginsburg, 2004). Both enzymes are
essential for post-translational g-carboxylation of clotting
factors, enabling them to attach to the phospholipid bilayer of
membranes as an essential prerequisite for blood coagulation
(Zhang and Ginsburg, 2004). The clinical features of VKCFD1
and -2 are highly variable and may include epistaxis,
(neonatal) intracranial hemorrhage, hemarthrosis, etc.,
although several patients remain asymptomatic (Zhang and
Ginsburg, 2004). Significant bleeding diathesis was observed
in cases 3 and 5, although it remains uncertain whether this
was due to the mild to moderate clotting factor deficiency. It
is interesting though that two cerebral aneurysms were
detected in case 1. Taken together with the potentially
subarachnoid hemorrhages in case 3, this may indicate that
patients with this disorder might have an increased risk for
cerebral aneurysms. By contrast, in PXE, cerebrovascular
complications are mostly ischemic (stroke).
In order to elucidate the molecular pathogenesis of this
phenotype, we initially focused on the VKORC1 gene, as it is
also located on chromosome 16p, albeit 15 Mb away from
ABCC6. However, sequencing of the whole coding region
did not reveal any causal mutation. In contrast, analysis of the
second gene involved in the clotting disorder, GGCX, has
revealed seven different mutations in six patients. Of these,
p.Q374X, p.W493S, p.R476C, and p.R476H are located in
the propeptide binding site of the g-carboxylase, important
for binding of the substrates. This site has been mapped to
amino acids 50–225, 349–500, and 425–513 (Yamada et al.,
1995; Wu et al., 1997; Lin et al., 2002). Thus, they could
result in a shorter residence time of the substrate on the
g-carboxylase with formation of poorly carboxylated, less
active proteins (Mutucumarana et al., 2000).
Site-directed mutagenesis demonstrated that regions
around residues 234, 406, and 503 partly define the
propeptide binding sites (Sugiura et al., 1996). The p.F299S,
p.G537Y, and p.G558S mutations may therefore also
influence the affinity of the g–carboxylase for its substrates.
Further bio- and immunohistochemical analysis of the
Table 4. Clinical, ultrastructural, and molecular characteristics of the PXE-like syndrome with a coagulation
disorder versus PXE and cutis laxa
PXE-like PXE Cutis laxa
Generalized skin folds/laxity Always present Not present Often present
Positive Von Kossa stain of the dermis Present Present Not present
Electron microscopy of the dermis Mineralized elastic fibers Mineralized elastic fibers Scarce and mottled elastic fibers
Retinopathy (AS/Pd’O) Present but mild Present and often severe Not present
Decreased visual acuity Not present 60% Infrequent
Clotting deficiency Always present Not described Not described
Atherosclerosis Subclinical in 50% (Sub)clinical in 55% Infrequent
Cerebral aneurysms Present Infrequent Infrequent
Abnormal bleeding tendency Present (50%) Infrequent (10%) Not described
ABCC6 mutations Not present Present (DR=96%) Not present
AS/Pd’O, angioid streaks/peau d’orange; DR, detection ratio; PXE, Pseudoxanthoma Elasticum.
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functional effects of these mutations is currently ongoing. It is
worthwhile mentioning that the vitamin K-dependent en-
zymes responsible for carboxylation of clotting factors are
also involved in modulating bone mineralization and in
preventing calcium precipitation in soft tissues (Price and
Williamson, 1985; Price et al., 1998). Our molecular results
are remarkable in that mutations in this phenotype seem to
occur typically in exons 8, 10, and 12. Mutations in these
exons have not been described so far in patients with the
hereditary coagulation disorder without the cutaneous
phenotype. It is our hypothesis that these exons are of critical
importance in domains that are essential in the activating role
of the GGCX enzyme in the coagulation cascade, but also for
the activation of other gla-proteins such as, for example,
matrix gla protein or osteocalcin. The latter are known
inhibitors of calcification. Hence, a decreased or
absent activation of such proteins can explain the calcifica-
tion and subsequent fragmentation of the elastic fibers. The
severity of the skin lesions might be due to the additive effect
of decreased or absent activity of multiple calcification
inhibitors.
A second theoretical possibility would be digenic
inheritance, in which a second, as yet unknown gene, is
responsible for the cutaneous phenotype. Linkage
analysis was possible in only one family without known
mutations; unfortunately, we were unable to obtain DNA
from a sib of the proband, essential for the interpretation of
the results.
Furthermore, apart from gene defects, the correct carboxy-
lation of clotting factors and of modulators of mineralization
in bone and soft tissues may depend on post-translational
maturation of enzymes (Wajih et al., 2004) as well as on cell
metabolic alterations affecting, for instance, the structural
organization of membranes of the endoplasmic reticulum
where carboxylating enzymes are located (Wallin et al.,
1999). Therefore, the problem is rather complex and the
involvement of vitamin K-dependent processes in miner-
alization of connective tissues and of elastic fibers in
particular is under investigation.
At present 10 cases with this peculiar phenotype have
been reported (Table 4). In the literature, the fundus
examination has always been considered normal. However,
owing to the very mild aspect of the retinopathy, it is possible
that small AS were missed. The fact that visual acuity has
always been reported as normal is yet another indicator of the
rather mild nature of the ocular features.
Bleeding tendency was very variable, as can be expected
from the hereditary form of VKCFD.
In conclusion, as (i) the fundus findings and the elastic
fiber mineralization in the skin of patients exclude any known
form of cutis laxa, and (ii) the distinct clinical manifestations
and severity of cutaneous and retinal symptoms, as well as
the slightly different ultrastructural features and the absence
of ABCC6 mutations in patients seem to exclude PXE, data
support the hypothesis that these patients suffer from a new
disorder. The molecular background of this peculiar pheno-
type, and more specifically the role of the GGCX gene, is
currently under investigation.
MATERIALS AND METHODS
Patients
The patients were clinically examined (skin evaluation, fundoscopy,
and cardiovascular work-up) at the Ghent University Hospital
(Belgium) (case 1), l’Hoˆpital Porte Madeleine, Orle´ans (France)
(cases 2 and 3), the University of Modena and Reggio Emilia,
Modena (Italy) (case 4). Patients 5 and 6 who reside in the United
States were not personally evaluated by the authors, but clinical data
were obtained from their medical specialists. The first four patients
had a full thickness skin biopsy taken in a skin lesion suggestive for
PXE. Biopsies were evaluated with light microscopy using hematox-
ylin and eosin, van Giesson (elastin), and Von Kossa (calcium) stains.
For electron microscopy, skin biopsy fragments were immedi-
ately fixed in 3% glutaraldehyde in Tyrode’s saline pH 7.2 for
2–4 hours at room temperature, washed in saline, post-fixed in 1%
osmium tetroxide in the same buffer for 1 hour, dehydrated in
ethanol and propylene oxide, and embedded in spurr resin. Semithin
sections were stained with 1% toluidine blue and observed by light
microscopy. Thin sections were stained with 1% uranyl acetate in
50% ethanol and lead citrate and observed in a Jeol EM1200
electron microscope. Skin biopsy fragments from patients 2 and 3
were first fixed in formalin and embedded in paraffin and then
rescued and embedded in spurr resin.
Coagulation assays were performed on citrated blood samples.
The activities of factors II, VII, IX, and X were measured in one-stage
clotting assays using Diagnostica Stago (Asnie`res sur Seine, France)
reagents. The prothrombin time was performed using the STA-
Neoplastin CI plus kit (Diagnostica Stago, France).
Informed consent was obtained from all patients and the
Declaration of Helsinki Principles was followed. This study was
approved by the Ethical Committee of the Ghent University Hospital.
Molecular analysis
Molecular analysis of the ABCC6 gene was performed in all six
patients and one additional, already reported, patient (Le Corvaisier-
Pieto et al., 1996), using PCR primers described by Wang et al.
(2001). In order to distinguish between ABCC6 and its two
pseudogenes a long-range PCR was performed of exons 1 through
10. The following primers were used: forward primer: 50-ATA CTC
AGT ATC AGC CAG GAT GTT-30 and reverse primer: 50-GGG ACT
CCG TTC AAA TCC CG-30. Subsequently, PCR reactions for the
separate exons were performed on the long-range amplicon. For the
detection of the deletion of exons 23–29, the primers described by le
Saux et al. (2001) were used.
The VKORC1 coding region was analyzed using following
primers: exon 1: forward primer 50-CTC CGT GGC TGG TTT TCT
C-30and reverse primer 50-CCG ATC CCA GAC TCC AGA AT-30;
exon 2: forward primer 50-ATG GGA GGT CGG GGA ACA-30 and
reverse primer 50-TGA GCA GCT AGC TGG CTG-30; exon 3:
forward primer 50-TCT GCC CTG GAG CCT CTT-30 and reverse
primer 50-CAC ATC TAG GGC CTT CTA G-30.
The GGCX coding region was analyzed using primers and PCR
conditions described by Oldenburg et al. (2000).
The whole coding region and intron/exon boundaries of ABCC6,
VKORC1, and GGCX were analyzed with direct sequencing using
an Applied Biosystems 3100 Sequencer, with ABI PRISM Big Dye
Terminator Cycle Sequencing Kit (Applied Biosystems, Lennik,
Belgium).
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Nucleotide numbers are derived from cDNA GGCX sequences
(GenBank accession no. BC013979). For cDNA numbering, þ 1
corresponds to the A of the ATG translation initiation codon.
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